- Forget any false sense of security: we are still at the start of the global pandemic
- ‘No kissing’: Amsterdam’s red light district reopens after coronavirus shutdown
- California rolls back reopening of bars, restaurants and indoor venues
- Man given ‘almost zero chance’ of Covid-19 survival due to return home
- Most People With Coronavirus Won’t Spread It. Why Do a Few Infect Many?
- A Virus Walks Into a Bar …
- World War C
- Childhood Multisystem Inflammatory Syndrome
- How Texas Swaggered Into a Coronavirus Disaster
- US visitors set to remain banned from entering EU
- No evidence that vitamin D prevents coronavirus
The New York Times: Austrian Ski Resort Has Record Rate of Coronavirus Antibodies, Study Finds | A study of residents in the Alpine ski resort of Ischgl, the site of Austria’s biggest coronavirus outbreak, has found 42% have antibodies for the virus, the highest rate ever proven, the university that carried out the study said on Thursday.
- How deadly is the coronavirus?
- Missteps undermined the US’s recovery
- ‘When Am I Coming Home?’
- Infektionsherd Fleischfabrik
- Los pioneros de la dexametasona en España
- Pékin se confine
- O que é? Há vacina? Vem aí a 2.ª vaga?
- Beijing coronavirus outbreak: city raises emergency level and grounds hundreds of flights
- Flushing the Toilet May Fling Coronavirus Aerosols All Over
- New Zealand puts Covid-19 quarantine in hands of military after border fiasco
- Berlins Tanz mit dem Virus
- Todos los contactos estrechos de cada caso positivo de coronavirus serán sometidos a una prueba PCR
- “Te quiero mucho papá, muchísimo”: la carta de una lectora a su padre antes de que falleciese
- L’application StopCovid collecte plus de données qu’annoncé
- Dexametasona é o maior avanço contra o vírus? Calma, diz o Infarmed
Results from the RECOVERY trial: Low-cost (5€) dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19.
BBC News: Dexamethasone is first life-saving coronavirus drug | A cheap and widely available drug called dexamethasone can help save the lives of patients who are seriously ill with coronavirus. Peter Horby: “This is the only drug so far that has been shown to reduce mortality – and it reduces it significantly. It’s a major breakthrough.” Martin Landray: “There is a clear, clear benefit. The treatment is up to 10 days of dexamethasone and it costs about £5 per patient. So essentially it costs £35 to save a life. This is a drug that is globally available.”
- Contact tracing is ‘best’ tool we have until there’s a vaccine, health experts say
- What the Pandemic Reveals About the Male Ego
- Beijing lockdown tightens as new coronavirus outbreak spreads
- ‘The country is adrift’: echoes of Spanish flu as Brazil’s Covid-19 catastrophe deepens
- Jede Treppe ein Marathon
- Mexico: Denn sie fürchten den Tod nicht
- “Hay más virus circulando ahora que antes del estado de alarma”
- Coronavirus : en Europe, la plupart des frontières rouvrent ce lundi
- Cytokine storms explained | Audio, 23 minutes.
- Doctors Are Covid’s First Historians (The New York Times)
- One third of UK women are suffering from lockdown loneliness (The Guardian)
- Fauci says US might not see ‘second wave’ of Covid-19 cases (The Guardian)
- Doctors warn that thousands could die of bowel cancer after halt in screening (The Guardian)
- ¿Se transmite por el aire el coronavirus?
- Leiden wir an einem gemeinschaftlichen Burn-out? (Die Zeit)
- Avoir 20 ans au temps du coronavirus (Le Monde)
- Not dying alone (The New England Journal of Medicine)
- Mutation Allows Coronavirus to Infect More Cells, Study Finds. Scientists Urge Caution (The New York Times)
- Poorest areas of England and Wales hit hardest by Covid-19 – ONS
- Was hat Schwedens Corona-Sonderweg gebracht?
- « Cela va au-delà de l’horreur »
- Lots of us are infected by the coronavirus — and don’t know it. Here’s what that means (The Washington Post)
- Amid pandemics and protests, is Britain facing its worst economy since the Great Frost of 1709? (The Washington Post)
- La expansión del virus por América preocupa a los expertos (El País)
- Coronavirus – au cœur de la bataille immunitaire contre le virus (Le Monde)
- When 511 Epidemiologists Expect to Fly, Hug and Do 18 Other Everyday Activities Again
- Are you immune?’ The new class system that could shape the Covid-19 world
- Fauci: coronavirus pandemic that ‘took over the planet’ is far from over
- Surgisphere: mass audit of papers linked to firm behind hydroxychloroquine Lancet study scandal
- Is British theatre about to go out of business?
- Cafe culture returns to France after lockdown – in pictures
- Life after Covid-19: stories of survival and loss from a Coventry hospital
- Without public faith in government actions, the UK will never beat Covid-19
- World Bank warns Covid-19 pandemic risks dramatic rise in poverty
- Workers in Tokyo’s red-light district to be tested for coronavirus after new spike
- ‘It feels endless’: four women struggling to recover from Covid-19
- ‘Cruise Ships on Land’: As Las Vegas Reopens, a Huge Test for Casinos
- Five ways New Zealand can keep Covid-19 cases at zero
- Health experts on the psychological cost of Covid-19.
- After six months of coronavirus, how close are we to defeating it?
- Coronavirus Shutdowns: Economists Look for Better Answers
- Amid reopenings and street protests, coronavirus transmission remains high in much of the U.S.
6 June. Nearly 600 US health workers died of Covid-19 – and the toll is rising – By Christina Jewett, Melissa Bailey and Danielle Renwick | The Guardian and KHN release new figures showing the harsh toll that the pandemic is taking on the frontline health workers.
First, a statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine. The summary: No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19.
Thereafter, a thoughful analysis of the challenges and limits of peer review published in The Guardian after The Lancet “made one of the biggest retractions in modern histroy”; an article published in El País about SARS-CoV-2 prevalence in Spain; and a feature published in Die Zeit showing how a small German hospital narrowly escaped disaster.
An eventful day: one paper retracted by the New England Journal of Medicine, another paper retracted by The Lancet; a warning why a COVID-19 vaccine should be a public good (The Guardian); a call by, the pioneer of the internet, for a universal right to internet access; and, finally, an excellent summary of “immunité croisée” – in French (Le Monde).
Hydroxychloroquine – no better than placebo? Telling a day full of turnaround.
The article of the day: Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 2020, June 3. Full-text: https://www.nejm.org/doi/full/10.1056/NEJMoa2016638